Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting

作     者：Minghan Qiu Shan Wu Xinrui Chen Huaqing Wang Minghan Qiu;Shan Wu;Xinrui Chen;Huaqing Wang

作者机构：Department of OncologyTianjin Union Medical CenterNankai UniversityTianjin 300191China The Institute of Translational MedicineTianjin Union Medical CenterNankai UniversityTianjin 300121China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2022年第19卷第8期

页      面：1117-1120页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Natural Science Foundation of China(Grant No.82070206) Tianjin Key Medical Discipline(Specialty)Construction Project(Grant No.TJYXZDXK-053B) 

主　　题：lymphoma ASCO mortality 

摘      要：Diffuse large B-cell lymphoma(DLBCL)is the most common non-Hodgkin’s lymphoma(NHL)and has high *** 30%–50%of patients develop relapsed/refractory(R/R)disease,which remains a major cause of *** recent years,a variety of novel therapies have emerged,including bispecific T-cell engagers(BiTEs),antibody–drug conjugates(ADCs),chimeric antigen receptor T cells(CAR-T),and selective BTK inhibitors,which have provided effective treatment strategies for patients with DLBCL1,***,the 58th Annual Meeting of the American Society of Clinical Oncology(ASCO)was held in Chicago,presenting cutting-edge studies in ***,we discuss a selection of interesting data on this topic.